Search

Your search keyword '"Sicilia, B"' showing total 205 results
Start Over Author "Sicilia, B"
205 results on '"Sicilia, B"'

51. DOP32 Long-term outcomes of enterocutaneous fistula complicating Crohn’s Disease: The ECUFIT study from GETECCU

Author

Rodríguez-Lago, I, primary, García Pérez, C, additional, Calafat, M, additional, Soto, M P, additional, Calvo, M, additional, Sánchez Rodríguez, E, additional, Caballol, B, additional, Vela, M, additional, Rivero, M, additional, Muñoz, F, additional, De Castro, L, additional, Calvet, X, additional, García-Alonso, F J, additional, Utrilla Fornals, A, additional, Ferreiro-Iglesias, R, additional, González-Muñoza, C, additional, Chaparro, M, additional, Luis, B, additional, Sicilia, B, additional, Alfambra, E, additional, Rodriguez, A, additional, Pérez Fernández, R, additional, Rodríguez, C, additional, Almela, P, additional, Argüelles, F, additional, Busquets, D, additional, Tamarit-Sebastián, S, additional, Reygosa Castro, C, additional, Jiménez, L, additional, Marín-Jiménez, I, additional, Alcaide, N, additional, Fernández-Salgado, E, additional, Iglesias Gómez, Á, additional, Ponferrada, Á, additional, Pajares, R, additional, Roncero, Ó, additional, Morales-Alvarado, V J, additional, Cabriada, J L, additional, Domènech, E, additional, and Barreiro-de Acosta, M, additional

Published
2021
Full Text
View/download PDF

52. P476 Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry

Author

Chaparro, M, primary, Garre, A, additional, Iborra, M, additional, Sierra, M, additional, Barreiro-de Acosta, M, additional, Fernández-Clotet, A, additional, de Castro, L, additional, Boscá-Watts, M, additional, Casanova, M J, additional, López-García, A, additional, Lorente, R, additional, Rodríguez, C, additional, Carbajo, A Y, additional, Arroyo, M T, additional, Gutiérrez, A, additional, Hinojosa, J, additional, Martínez-Pérez, T, additional, Villoria, A, additional, Bermejo, F, additional, Busquets, D, additional, Camps, B, additional, Cañete, F, additional, Manceñido, N, additional, Monfort, D, additional, Navarro-Llavat, M, additional, Pérez-Calle, J L, additional, Ramos, L, additional, Rivero, M, additional, Angueira, T, additional, Camo, P, additional, Carpio, D, additional, García-de-la-Filia, I, additional, González-Muñoza, C, additional, Hernández, L, additional, Huguet, J M, additional, Morales, V J, additional, Sicilia, B, additional, Vega, P, additional, Domènech, E, additional, and Gisbert, J P, additional

Published
2021
Full Text
View/download PDF

53. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry

Author

Andujar, X, Loras, C, Gonzalez, B, Socarras, M, Sanchiz, V, Bosca, M, Domenech, E, Calafat, M, Rodriguez, E, Sicilia, B, Calvet, X, Barrio, J, Guardiola, J, Iglesias, E, Casanova, MJ, Ber, Y, Monfort, D, Lopez-Sanroman, A, Rodriguez-Lago, I, Bujanda, L, Marquez, L, Martin-Arranz, MD, Zabana, Y, Fernandez-Banares, F, Esteve, M, Panes, J, Minguez, M, Sanchez, VG, Perez-Gisbert, J, Gomollon, F, Piqueras, M, Cabriada, JL, and Andreu, M

Subjects
Crohn's disease, Endoscopic balloon dilation, Inflammatory bowel disease
Abstract

Background There is no information regarding the outcome of Crohn's disease (CD) patients treated with endoscopic balloon dilation (EBD) in non-referral hospitals, nor on the efficacy of EBD in ulcerative colitis (UC). We report herein the results of the largest series published to date. Aim To assess the efficacy and safety of EBD for inflammatory bowel disease (IBD) stenosis performed in 19 hospitals with different levels of complexity and to determine factors related to therapeutic success. Methods We identified IBD patients undergoing EBD in the ENEIDA database. Efficacy of EBD was compared between CD and UC and between secondary and tertiary hospitals. Predictive factors of therapeutic success were assessed with multivariate analysis. Results Four-hundred dilations (41.2% anastomotic) were performed in 187 IBD patients (13 UC/Indeterminate colitis). Technical and therapeutic success per dilation was achieved in 79.5% and 55.3%, respectively. Therapeutic success per patient was achieved in 78.1% of cases (median follow-up: 40 months) with 49.7% requiring more than one dilation. No differences related to either diagnosis or hospital complexity was found. Technical success [OR 4.12 (95%CI 2.4-7.1)] and not receiving anti-TNF at the time of dilation [OR 1.7 (95% CI 1.1-2.6)] were independently related to therapeutic success per dilation. A stricture length

Published
2020

54. Impact of comorbidities on anti-TNF alpha response and relapse in patients with inflammatory bowel disease: the VERNE study

Author

Marin-Jimenez, I, Bastida, G, Fores, A, Garcia-Planella, E, Arguelles-Arias, F, Sarasa, P, Tagarro, I, Fernandez-Nistal, A, Montoto, C, Aguas, M, Santos-Fernandez, J, Bosca-Watts, MM, Ferreiro, R, Merino, O, Aldeguer, X, Cortes, X, Sicilia, B, Mesonero, F, and Barreiro-de Acosta, M

Subjects
Crohn's disease, TNF-alpha, immune response, ulcerative colitis, digestive system diseases
Abstract

Objective To evaluate the impact of comorbidities and extraintestinal manifestations of inflammatory bowel disease on the response of patients with inflammatory bowel disease to antitumour necrosis factor alpha (anti-TNF alpha) therapy. Design Data from 310 patients (194 with Crohn's disease and 116 with ulcerative colitis) treated consecutively with the first anti-TNF alpha in 24 Spanish hospitals were retrospectively analysed. Univariate and multivariate logistic regression analyses were performed to assess the associations between inflammatory bowel disease comorbidities and extraintestinal manifestations with anti-TNF alpha treatment outcomes. Key clinical features, such as type of inflammatory bowel disease and concomitant treatments, were included as fixed factors in the model. Results Multivariate logistic regression analyses (OR, 95% CI) showed that chronic obstructive pulmonary disease (2.67, 1.33 to 5.35) and hepato-pancreato-biliary diseases (1.87, 1.48 to 2.36) were significantly associated with primary non-response to anti-TNF alpha, as was the use of corticosteroids and the type of inflammatory bowel disease (ulcerative colitis vs Crohn's disease). It was also found that myocardial infarction (3.30, 1.48 to 7.35) and skin disease (2.73, 1.42 to 5.25) were significantly associated with loss of response, along with the use of corticosteroids and the type of inflammatory bowel disease (ulcerative colitis vs Crohn's disease). Conclusions Our results suggest that the presence of some comorbidities in patients with inflammatory bowel disease, such as chronic obstructive pulmonary disease and myocardial infarction, and of certain extraintestinal manifestations of inflammatory bowel disease, such as hepato-pancreato-biliary conditions and skin diseases, appear to be related to failure to anti-TNF alpha treatment. Therefore, their presence should be considered when choosing a treatment.

Published
2020

55. Low adhesion to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFEII registry of GETECCU

Author

Abdo, YZ, de Francisco, R, Rodriguez-Lago, I, Chaparro, M, Gomollon, F, Piqueras, M, Llao, J, Sicilia, B, Domenech, E, Garcia-Bosch, O, de Castro, L, Calvet, X, Morales, V, Rivero, M, Lucendo, AJ, Navarro, P, Marquez, L, Busquets, D, Guardiola, J, Gordillo, J, Iglesias, E, Beltran, B, Sese, E, Ferreiro-Iglesias, R, Francisco, M, Pajares, R, Algaba, A, Vicente, R, Benitez, O, Aceituno, M, Riestra, S, Rodriguez-Pescador, A, Gisbert, JP, Arroyo, MT, Mena, R, Sainz, E, Arias-Garcia, L, Manosa, M, Navarro, M, Sanroman, L, Villoria, A, Delgado-Villena, P, Garcia, MJ, Angueira, T, Minguez, M, Murciano, F, Arajol, C, and Esteve, M

Published
2020

56. Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn's disease (CD) in real life: Interim analysis of the SUSTAIN study

Author

Chaparro, M, Sulleiro, S, Baston-Rey, I, Rodriguez, C, Garcia-Tercero, I, Ramirez, P, Garcia-Lopez, S, Rojas-Feria, M, Gutierrez, A, Malaves, J, Garcia-Sepulcre, M, Sicilia, B, Bermejo, F, Rodriguez-Moranta, F, Arguelles, F, Marin, I, Leo, E, Arroyo, M, Garcia, M, Vazquez, J, Ginard, D, Cadilla, J, de Celix, C, Garcia-Herola, A, Hernandez-Camba, A, Martin-Arranz, M, Riestra, S, Varela, P, Velayos, B, Busquets, D, Duenas, C, Fernandez-Salgado, E, Martinez-Montiel, P, Diz-Lois, M, Gonzalez-Lama, Y, Munagorri, A, Navarro-Llavat, M, Guisado, C, Barreiro-de Acosta, M, Gisbert, J, and SUSTAIN Study Grp

Published
2020

57. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry (vol 34, pg 1112, 2020)

Author

And?jar X, Loras C, Gonz?lez B, Socarras M, Sanchiz V, Bosc? M, Domenech E, Calafat M, Rodr?guez E, Sicilia B, Calvet X, Barrio J, Guardiola J, Iglesias E, Casanova M, Ber Y, Monfort D, L?pez-Sanroman A, Rodr?guez-Lago I, Bujanda L, M?rquez L, Mart?n-Arranz M, Zabana Y, Fernandez-Ba?ares F, Esteve M, and ENEIDA Registry GETECCU

Abstract

Javier P. Gisbert was listed incorrectly as Javier Perez-Gisbert.

Published
2020

58. Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry

Author

Colomino, M, Beltran, B, Fernandez-Clotet, A, Flores, E, Navarro, P, Rivero, M, Gutierrez, A, Sierra-Ausin, M, Mesonero, F, Ferreiro-Iglesias, R, Hinojosa, J, Calvet, X, Sicilia, B, Gonzalez-Munoza, C, Antolin, B, Vivo, M, Carbajo, A, Garcia, S, Martin-Cardona, A, Marin, G, Martin-Arranz, M, De Francisco, R, Canete, F, Carlos, T, Gomollon, F, Lorente, R, Rodriguez-Lago, I, Fores-Bosch, A, Bernardos, E, Ramos, L, Delgado, P, Hernandez, A, Van Domselaar, M, Hervas, D, Domenech, E, and Nos, P

Published
2020

59. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Author

Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, and GETECCU study group

Subjects
Adult, Male, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, Communicable Diseases, Inflammatory bowel disease, Vedolizumab, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, Interquartile range, Internal medicine, medicine, Humans, Pharmacology (medical), Prospective Studies, Registries, Adverse effect, Prospective cohort study, Hepatology, business.industry, Proportional hazards model, Remission Induction, Gastroenterology, Middle Aged, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, Discontinuation, Treatment Outcome, Spain, 030220 oncology & carcinogenesis, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, business, Follow-Up Studies, medicine.drug
Abstract

Background: Effectiveness of vedolizumab in real world clinical practice is unknown. Aim: To evaluate the short and long-term effectiveness of vedolizumab in patients with inflammatory bowel disease (IBD). Methods: Patients who received at least 1 induction dose of vedolizumab were included. Effectiveness was defined based on Harvey-Bradshaw index (HBI) in Crohn's disease (CD) and Partial Mayo Score (PMS) in ulcerative colitis (UC). Short-term response was assessed at week 14. Variables associated with short-term remission were identified by logistic regression analysis. The Kaplan-Meier method was used to evaluate the long-term durability of vedolizumab treatment. Cox model was used to identify factors associated with discontinuation of treatment and loss of response. Results: 521 patients were included (median follow-up 10 months [interquartile range 5-18 months]). At week 14, 46.8% had remission and 15.7% clinical response. CD (vs UC), previous surgery, higher CRP concentration and disease severity at baseline were significantly associated with impaired response. The rate of vedolizumab discontinuation was 37% per patient-year of follow-up (27.6% in UC and 45.3% in CD, P < 0.01). CD (vs UC), anaemia at baseline, steroids during induction and CRP concentration were associated with lower durability of treatment. Seven per cent of patients developed adverse events, infections being the most frequent. Conclusions: Over 60% of IBD patients respond to vedolizumab. Many patients discontinue treatment over time. CD and disease burden impair both short- and long-term response. Vedolizumab seems to be safe in clinical practice.

Published
2018
Full Text
View/download PDF

60. MULTICENTER PROSPECTIVE RANDOMIZED STUDY TO COMPARE ENDOSCOPIC TREATMENT OF STRICTURES IN CROHN´S DISEASE (CD): SELF-EXPANDING METAL STENTS (SEMS) VS ENDOSCOPIC BALLOON DILATION (EBD). PROTDILAT STUDY

Author

Andújar, X, additional, Loras, C, additional, Gornals, JB, additional, Guardiola, J, additional, Sanchiz, V, additional, Bosca, M, additional, Brullet, E, additional, Sicilia, B, additional, Naranjo, A, additional, Dueñas, C, additional, Foruny, JR, additional, Busquets, D, additional, Monfort, D, additional, Martín-Arranz, MD, additional, Barrio, J, additional, Pineda, JR, additional, González-Huix, F, additional, Pérez-Roldán, F, additional, Pons, V, additional, González, B, additional, Sainz, E, additional, Reyes-Moreno, J, additional, Fernández-Bañares, F, additional, and Esteve, M, additional

Published
2020
Full Text
View/download PDF

61. P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU

Author

Chaparro, M, primary, Barreiro-de Acosta, M, additional, Benítez, J M, additional, Cabriada, J L, additional, Casanova, M J, additional, Ceballos, D, additional, Esteve, M, additional, Fernández, H, additional, Ginard, D, additional, Gomollón, F, additional, Lorente, R, additional, Nos, P, additional, Riestra, S, additional, Rivero, M, additional, Robledo, P, additional, Rodríguez, C, additional, Sicilia, B, additional, Torrella, E, additional, Garre, A, additional, Rodríguez-Artalejo, F, additional, García-Esquinas, E, additional, and Gisbert, J P, additional

Published
2020
Full Text
View/download PDF

62. P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study

Author

Chaparro, M, primary, Sulleiro, S, additional, Bastón-Rey, I, additional, Rodríguez, C, additional, García-Tercero, I, additional, Ramírez, P, additional, García-López, S, additional, Rojas-Feria, M, additional, Gutiérrez, A, additional, Huguet Malavés, J M, additional, García-Sepulcre, M F, additional, Sicilia, B, additional, Bermejo, F, additional, Rodríguez-Moranta, F, additional, Argüelles, F, additional, Marín, I, additional, Leo, E, additional, Arroyo, M, additional, García, M J, additional, Vázquez, J M, additional, Ginard, D, additional, Martínez Cadilla, J, additional, Rubín de Célix, C, additional, García-Herola, A, additional, Hernández-Camba, A, additional, Martín-Arranz, M D, additional, Riestra, S, additional, Varela, P, additional, Velayos, B, additional, Busquets, D, additional, Dueñas, C, additional, Fernández-Salgado, E, additional, Martínez-Montiel, P, additional, Diz-Lois, M T, additional, González-Lama, Y, additional, Muñagorri, A, additional, Navarro-Llavat, M, additional, Guisado, C, additional, Barreiro-de Acosta, M, additional, and Gisbert, J P, additional

Published
2020
Full Text
View/download PDF

63. P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry

Author

Iborra Colomino, M I, primary, Beltrán, B, additional, Fernández-Clotet, A, additional, Iglesias Flores, E, additional, Navarro, P, additional, Rivero, M, additional, Gutiérrez, A, additional, Sierra-Ausin, M, additional, Mesonero, F, additional, Ferreiro-Iglesias, R, additional, Hinojosa, J, additional, Calvet, X, additional, Sicilia, B, additional, González-Muñoza, C, additional, Antolín, B, additional, González Vivo, M, additional, Carbajo, A Y, additional, García, S, additional, Martín-Cardona, A, additional, Surís Marín, G, additional, Martín-Arranz, M D, additional, De Francisco, R, additional, Cañete, F, additional, Carlos, T, additional, Gomollón, F, additional, Lorente, R, additional, Rodríguez-Lago, I, additional, Forés-Bosch, A, additional, Bernardos, E, additional, Ramos, L, additional, Delgado, P, additional, Hernández, A, additional, Van Domselaar, M, additional, Hervás, D, additional, Domènech, E, additional, and Nos, P, additional

Published
2020
Full Text
View/download PDF

64. P774 Low adhesion to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFEII registry of GETECCU

Author

Zabana Abdo, Y, primary, de Francisco, R, additional, Rodríguez-Lago, I, additional, Chaparro, M, additional, Gomollón, F, additional, Piqueras, M, additional, Llaó, J, additional, Sicilia, B, additional, Domènech, E, additional, García-Bosch, O, additional, de Castro, L, additional, Calvet, X, additional, Morales, V, additional, Rivero, M, additional, Lucendo, A J, additional, Navarro, P, additional, Márquez, L, additional, Busquets, D, additional, Guardiola, J, additional, Gordillo, J, additional, Iglesias, E, additional, Beltrán, B, additional, Sesé, E, additional, Ferreiro-Iglesias, R, additional, Francisco, M, additional, Pajares, R, additional, Algaba, A, additional, Vicente, R, additional, Benítez, O, additional, Aceituno, M, additional, Riestra, S, additional, Rodríguez-Pescador, A, additional, Gisbert, J P, additional, Arroyo, M T, additional, Mena, R, additional, Sáinz, E, additional, Arias-García, L, additional, Mañosa, M, additional, Navarro, M, additional, Sanromán, L, additional, Villória, A, additional, Delgado-Villena, P, additional, García, M J, additional, Angueira, T, additional, Mínguez, M, additional, Murciano, F, additional, Arajol, C, additional, and Esteve, M, additional

Published
2020
Full Text
View/download PDF

65. Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study

Author

Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, Gutiérrez A, Gordillo Ábalos J, de Castro L, Iborra M, Carbajo AY, Taxonera C, Rodríguez-Lago I, Mesonero F, de Francisco R, Gómez-Gómez GJ, Chaparro M, Tardillo CA, Rivero M, Algaba A, Martín Arranz E, Cañete F, Vicente R, Sicilia B, Antolín B, Prieto V, Márquez L, Benítez JM, Camo P, Piqueras M, Gargallo CJ, Hinojosa E, Huguet JM, Pérez Calle JL, Van Domselaar M, Rodriguez C, Calvet X, Muñoz-Villafranca C, García-Sepulcre MF, Munoz-Garrido P, Fernández-Clotet A, Gómez Irwin L, Hernández S, Guardiola J, Sempere L, González Muñoza C, Hernández V, Beltrán B, Barrio J, Alba C, Moraleja I, López-Sanromán A, Riestra S, Martínez Montiel P, Garre A, Arranz L, García MJ, Martín Arranz MD, Corsino P, Arias L, Fernández-Salazar L, Fernández-Pordomingo A, Andreu M, Iglesias E, Ber Y, Mena R, Arroyo Villarino MT, Mora M, Ruiz L, López-Serrano P, Blazquez I, Villoria A, Fernández M, Bermejo F, Banales JM, Domènech E, and Gisbert JP

Subjects
endocrine system diseases, digestive, oral, and skin physiology, inflammatory bowel disease, malignancy, primary sclerosing cholangitis, digestive system, digestive system diseases
Abstract

Primary sclerosing cholangitis (PSC) is usually associated with inflammatory bowel disease (IBD). An increased risk of malignancies, mainly colorectal cancer (CRC) and cholangiocarcinoma (CCA), has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies.

Published
2019

66. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers

Author

Manosa, M, Chaparro, M, Juan, A, Arajol, C, Alfaro, I, Minguez, M, Velayos, B, Benitez, JM, Mesonero, F, Sicilia, B, Zabana, Y, Villoria, A, Gisbert, JP, and Domenech, E

Abstract

OBJECTIVES:Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate the spread and recurrence of cancer. This study assesses the impact of the use of IMTs on the development of incident cancers (recurrent or new) in patients with inflammatory bowel disease (IBD) and a history of malignancy.METHODS:Patients with IBD included in the ENEIDA registry with a history of cancer without being exposed to IMTs were identified and retrospectively reviewed and compared regarding further treatment with IMTs or not by means of a log-rank test.RESULTS:Overall, 520 patients with previous extracolonic cancer naive to IMTs before the diagnosis of cancer were identified. Of these, 146 were subsequently treated with IMTs (exposed), whereas 374 were not (nonexposed). The proportion of patients with incident cancers was similar in both exposed (16%) and nonexposed (18%) patients (P = 0.53); however, there was more than a 10-year difference in the age at index cancer between these 2 groups. Cancer-free survival was 99%, 98%, and 97% at 1, 2, and 5 years in exposed patients, and 97%, 96%, and 92% at 1, 2, and 5 years in non-exposed patients, respectively (P = 0.03). No differences in incident cancer rates were observed between exposed and nonexposed patients when including only those who were exposed within the first 5 years after cancer diagnosis.DISCUSSION:In patients with IBD and a history of cancer not related to immunosuppression, the use of IMTs is not associated with an increased risk of new or recurrent cancers even when IMTs are started early after cancer diagnosis.

Published
2019

67. Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)

Author

Sainz Arnau, E., Zabana, Y., Miguel, I., Fernandez Clotet, A., Casanova, M. J., Martin, M. D., Pico, M. D., Alfambra, E., Rodriguez, I., Munoz, F., Dominguez, M., Iglesias, E., Busquets, D., Gutierrez, A., Canete, F., Nunez, L., Taxonera, C., Beltran, B., Camps, B., Calvet, X., Navarro, P., Calafat, M., Ferreiro-Iglesias, R., Gonzalez-Munoza, C., Sicilia, B., Rodriguez, C., Carbajo, A. Y., Domselaar, M., Vicente, R., Piqueras, M., Munoz, M. C., Abad, A., Algaba, A., Martinez, P., Vela, M. I., Antolin, B., Huguet, J. M., Luis Bujanda, Lorente, R. H., Almela, P., Garcia, M. J., Ramirez La Piscina, P., Pajares, R., Perez-Martinez, I., Lucendo, A. J., Merino, O., Legido, J., Vera, I., Morales, V. J., and Esteve, M.

Published
2019

68. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

Author

Chaparro, M, Garre, A, Ricart, E, Iglesias-Flores, E, Taxonera, C, Manosa, M, Mendoza, IV, Minguez, M, Arguelles, F, Parga, LD, Arroyo, M, Lopez-Sanroman, A, Tirado, MR, Guardiola, J, Arranz, MDM, Beltran, B, Barrio, J, Riestra, S, Garcia-Planella, E, Calvet, X, Alcain, G, Sicilia, B, Garcia, S, Esteve, M, Marquez, L, Salazar, LIF, Casbas, AG, Piqueras, M, Bermejo, F, Calle, JLP, Hinojosa, J, Perez, AR, Aldeguer, X, Sepulcre, MFG, Bujanda, L, Montiel, PM, Poyatos, RL, Gutierrez, CR, Merino, O, Cabriada, JL, Roncero, O, Cara, PR, Navarro-Llavat, M, Ber, Y, Madrigal, RE, Van Domselaar, M, Barreiro-de Acosta, M, Llao, J, Ramos, L, Riera, J, Villarin, AJL, Gonzalez, ER, Malaves, JMH, Villafranca, CM, Almela, P, Charro, M, de la Piscina, PR, Sese, E, Lacruz, AA, Khorrami, S, Alvarado, VJM, Gil, JL, Martinez, AMT, Villaroya, RP, Acevedo, J, Herola, AG, Villalba, LH, Munoz, E, Duran, MTN, Menacho, M, Lopez, VMN, Retamero, MD, Bernardo, D, Muriel, A, Domenech, E, Gisbert, JP, and ENEIDA Study Grp

Abstract

Background Cohort studies comparing the characteristics of childhood-onset and adulthood-onset inflammatory bowel disease (IBD) in the biologics era are scarce. Aim To compare disease characteristics, the use of immunomodulators and biologic agents and the need for surgery between childhood- and adulthood-onset IBD. Methods Inflammatory bowel disease patients from the ENEIDA registry diagnosed between 2007 and 2017 were included. The childhood-onset cohort comprised patients diagnosed at 16 years. The cumulative incidences of immunosuppressive therapy, biologic therapy and surgery were estimated using Kaplan-Meier curves, compared by the log-rank test. Cox regression analysis was performed to identify potential predictive factors of treatment with immunosuppressants, biologic agents or surgery. Results The adulthood-onset cohort comprised 21 200 patients out of 20 354 (96%) and the childhood-onset cohort 846 (4%). Median follow-up was 54 months in the childhood-onset cohort and 38 months in the adulthood-onset cohort (P < 0.01). Proportions of Crohn's disease, ileocolonic involvement and inflammatory behaviour at diagnosis were higher in the childhood-onset cohort. In the multivariate analysis, after adjusting for sex, type of IBD, extraintestinal manifestations, family history and smoking habit, childhood-onset IBD was associated with higher risk of immunomodulator use (hazard ratio [HR] = 1.2, 95% confidence interval [95% CI] = 1.1-1.2) and higher probability of receiving biologic treatment (HR = 1.2, 95% CI = 1.1-1.3). However, childhood-onset IBD was not associated with higher risk of surgery (HR = 0.9, 95% CI = 0.8-1.2). Conclusions Childhood-onset IBD has differential characteristics and higher risk of treatment with immunomodulators and biologic agents, compared with adulthood-onset IBD. Nevertheless, paediatric IBD is not associated with higher risk of surgery.

Published
2019

70. Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry

Author

Calafat, M, Manosa, M, Panes, J, Nos, P, Iglesias, E, Vera, I, Lopez-Sanroman, A, Guardiola, J, Taxonera, C, Minguez, M, Martin, MD, de Castro, L, Riestra, S, Rivero, M, Garcia-Planella, E, Calvet, X, Garcia-Lopez, S, Andreu, M, Gomollon, F, Barrio, J, Esteve, M, Rodriguez, A, Gisbert, JP, Gutierrez, A, Hinojosa, J, Arguelles, F, Busquets, D, Bujanda, L, Lazaro, J, Sicilia, B, Merino, O, Martinez, P, Bermejo, F, Lorente, R, Barreiro-de-Acosta, M, Rodriguez, C, Fe, M, Piqueras, M, Romero, P, Rodriguez, E, Roncero, O, Llao, J, Alcain, G, Riera, J, Sierra, M, Salazar, LIF, Jair, V, Navarro, M, Montoro, MA, Munoz, C, Lucendo, AJ, Van Domselaar, M, Moraleja, I, Huguet, M, Ramos, L, Ramirez, P, Almeda, P, Pajares, R, Khorrami, S, Madrigal, RE, Sese, E, Trapero, AM, Legido, J, Abad, A, Canete, F, Cabre, E, and Domenech, E

Published
2019

72. P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry

Author

Calafat, M, primary, Mañosa, M, additional, Panes, J, additional, Nos, P, additional, Iglesias, E, additional, Vera, I, additional, López-Sanromán, A, additional, Guardiola, J, additional, Taxonera, C, additional, Mínguez, M, additional, Martín, M D, additional, de Castro, L, additional, Riestra, S, additional, Rivero, M, additional, García-Planella, E, additional, Calvet, X, additional, García-López, S, additional, Andreu, M, additional, Gomollón, F, additional, Barrio, J, additional, Esteve, M, additional, Rodríguez, A, additional, Gisbert, J P, additional, Gutierrez, A, additional, Hinojosa, J, additional, Argüelles, F, additional, Busquets, D, additional, Bujanda, L, additional, Lázaro, J, additional, Sicilia, B, additional, Merino, O, additional, Martínez, P, additional, Bermejo, F, additional, Lorente, R, additional, Barreiro-de-Acosta, M, additional, Rodríguez, C, additional, Fe, M, additional, Piqueras, M, additional, Romero, P, additional, Rodríguez, E, additional, Roncero, Ó, additional, Llaó, J, additional, Alcaín, G, additional, Riera, J, additional, Sierra, M, additional, Fdez. Salazar, L I, additional, Jair, V, additional, Navarro, M, additional, Montoro, M A, additional, Muñoz, C, additional, Lucendo, A J, additional, Van Domselaar, M, additional, Moraleja, I, additional, Huguet, J M, additional, Ramos, L, additional, Ramírez, P, additional, Almeda, P, additional, Pajares, R, additional, Khorrami, S, additional, Madrigal, R E, additional, Sesé, E, additional, Trapero, A M, additional, Legido, J, additional, Abad, Á, additional, Cañete, F, additional, Cabré, E, additional, and Domènech, E, additional

Published
2019
Full Text
View/download PDF

73. P443 Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)

Author

Sainz Arnau, E, primary, Zabana, Y, additional, Miguel, I, additional, Fernández Clotet, A, additional, Casanova, M J, additional, Martín, M D, additional, Picó, M D, additional, Alfambra, E, additional, Rodriguez, I, additional, Muñoz, F, additional, Domínguez, M, additional, Iglesias, E, additional, Busquets, D, additional, Gutiérrez, A, additional, Cañete, F, additional, Nuñez, L, additional, Taxonera, C, additional, Beltrán, B, additional, Camps, B, additional, Calvet, X, additional, Navarro, P, additional, Calafat, M, additional, Ferreiro-Iglesias, R, additional, González-Muñoza, C, additional, Sicilia, B, additional, Rodríguez, C, additional, Carbajo, A Y, additional, van Domselaar, M, additional, Vicente, R, additional, Piqueras, M, additional, Muñoz, M C, additional, Abad, À, additional, Algaba, A, additional, Martínez, P, additional, Vela, M I, additional, Antolín, B, additional, Huguet, J M, additional, Bujanda, L, additional, Lorente, R H, additional, Almela, P, additional, García, M J, additional, Ramírez de la Piscina, P, additional, Pajares, R, additional, Pérez-Martínez, I, additional, Lucendo, A J, additional, Merino, O, additional, Legido, J, additional, Vera, I, additional, Morales, V J, additional, and Esteve, M, additional

Published
2019
Full Text
View/download PDF

74. P439 Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry

Author

Casanova, M J, primary, Chaparro, M, additional, Mínguez, M, additional, Ricart, E, additional, Taxonera, C, additional, García-López, S, additional, Guardiola, J, additional, López-San Román, A, additional, Iglesias, E, additional, Beltrán, B, additional, Sicilia, B, additional, Vera, M I, additional, Hinojosa, J, additional, Riestra, S, additional, Domènech, E, additional, Calvet, X, additional, Pérez-Calle, J L, additional, Martín-Arranz, M D, additional, Aldeguer, X, additional, Rivero, M, additional, Monfort, D, additional, Barrio, J, additional, Esteve, M, additional, Márquez, L, additional, Lorente, R, additional, García-Planella, E, additional, de Castro, L, additional, Bermejo, F, additional, Merino, O, additional, Rodríguez-Pérez, A, additional, Martínez-Montiel, P, additional, Van Domselaar, M, additional, Alcaín, G, additional, Domínguez-Cajal, M, additional, Muñoz, C, additional, Gomollón, F, additional, Fernández-Salazar, L, additional, García-Sepulcre, M F, additional, Rodríguez-Lago, I, additional, Gutiérrez, A, additional, Argüelles-Arias, F, additional, Rodriguez, C, additional, Rodríguez, G E, additional, Bujanda, L, additional, Llaó, J, additional, Varela, P, additional, Ramos, L, additional, Huguet, J M, additional, Almela, P, additional, Romero, P, additional, Navarro-Llavat, M, additional, Abad, Á, additional, Ramírez-de la Piscina, P, additional, Lucendo, A J, additional, Sesé, E, additional, Madrigal, R E, additional, Charro, M, additional, García-Herola, A, additional, Pajares, R, additional, Khorrami, S, additional, and Gisbert, J P, additional

Published
2019
Full Text
View/download PDF

75. P309 Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study

Author

Marín-Jiménez, I, primary, Bastida, G, additional, Forés, A, additional, García-Planella, E, additional, Argüelles-Arias, F, additional, Sarasa, P, additional, Tagarro, I, additional, Fernández-Nistal, A, additional, Montoto, C, additional, Aguas, M, additional, Santos-Fernández, J, additional, Boscá, M, additional, Ferreiro-Iglesias, R, additional, Merino, O, additional, Aldeguer, X, additional, Cortés, X, additional, Sicilia, B, additional, Mesonero, F, additional, and Barreiro-de Acosta, M, additional

Published
2019
Full Text
View/download PDF

76. P127 Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study)

Author

Bastida, G, primary, Marín-Jiménez, I, additional, Forés, A, additional, García-Planella, E, additional, Argüelles-Arias, F, additional, Sarasa, P, additional, Tagarro, I, additional, Fernández-Nistal, A, additional, Montoto, C, additional, Aguas, M, additional, Santos-Fernández, J, additional, Boscá, M, additional, Ferreiro-Iglesias, R, additional, Merino, O, additional, Aldeguer, X, additional, Cortés, X, additional, Sicilia, B, additional, Mesonero, F, additional, and Barreiro-de Acosta, M, additional

Published
2019
Full Text
View/download PDF

78. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

Author

Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, and Gisbert JP

Subjects
Male, Constriction, Pathologic, Inflammatory bowel disease, Gastroenterology, Deprescriptions, 0302 clinical medicine, Crohn Disease, Recurrence, Risk Factors, Medicine, Young adult, Mesalamine, Aged, 80 and over, Incidence, Incidence (epidemiology), Remission Induction, Age Factors, Middle Aged, Antirheumatic Agents, 030220 oncology & carcinogenesis, Retreatment, Disease Progression, Female, 030211 gastroenterology & hepatology, Tumor necrosis factor alpha, Adult, medicine.medical_specialty, Adolescent, Drug-Related Side Effects and Adverse Reactions, Colon, Young Adult, 03 medical and health sciences, Ileum, Internal medicine, Humans, Immunologic Factors, Colitis, Aged, Proportional Hazards Models, Retrospective Studies, Hepatology, Tumor Necrosis Factor-alpha, business.industry, Proportional hazards model, Adalimumab, Retrospective cohort study, Protective Factors, Inflammatory Bowel Diseases, medicine.disease, Infliximab, Discontinuation, Methotrexate, Colitis, Ulcerative, business, Follow-Up Studies
Abstract

OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included. RESULTS: A total of 1,055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn's disease and ulcerative colitis patients, respectively. In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year. The treatment with adalimumab vs. infliximab (hazard ratio (HR)=1.29; 95% confi dence interval (CI)= 1.01-1.66), elective discontinuation of anti-TNFs (HR=1.90; 95% CI= 1.07-3.37) or discontinuation because of adverse events (HR= 2.33; 95% CI= 1.27-2.02) vs. a top-down strategy, colonic localization (HR= 1.51; 95% CI= 1.13-2.02) vs. ileal, and stricturing behavior (HR= 1.5; 95% CI= 1.09-2.05) vs. inflammatory were associated with a higher risk of relapse in Crohn's disease patients, whereas treatment with immunomodulators after discontinuation (HR= 0.67; 95% CI= 0.51-0.87) and age (HR= 0.98; 95% CI= 0.97-0.99) were protective factors. None of the factors were predictive in ulcerative colitis patients. Retreatment of relapse with the same anti-TNF was effective (80% responded) and safe. CONCLUSIONS: The incidence rate of infl ammatory bowel disease relapse after anti-TNF discontinuation is relevant. Some predictive factors of relapse after anti-TNF withdrawal have been identifi ed. Retreatment with the same anti-TNF drug was effective and safe.

Published
2017

79. P397 Effectiveness of vedolizumab (VDZ) for the induction of remission in inflammatory bowel disease (IBD): Results from the Spanish Eneida Registry

Author

Chaparro, M, primary, Garre, A, additional, Alfaro, I, additional, Iborra, M, additional, Mesonero, P, additional, Vera Mendoza, I, additional, Rodríguez, A, additional, Miquel-Cusachs, J, additional, Riestra, S, additional, Navarro, P, additional, De Castro Parga, L, additional, González-Muñoza, C, additional, Rivero, M, additional, Mañosa, M, additional, Fernández Salazar, L, additional, Jiménez, N, additional, Guardiola, J, additional, Cabriada, J, additional, Gutiérrez Casbas, A, additional, Sicilia, B, additional, Pérez Calle, J L, additional, Piqueras, M, additional, Algaba, A, additional, Roncero, O, additional, Bargallo, A, additional, Sainz, E, additional, Barrio, J, additional, Calvet, X, additional, García, A, additional, Llorente Barrio, M, additional, Llorente Poyatos, R, additional, Almela, P, additional, Madrigal, R, additional, Lucendo Villarín, A J, additional, Pajares, R, additional, Van Domselaar, M, additional, Legido Gil, J, additional, and Gisbert, J P, additional

Published
2018
Full Text
View/download PDF

80. P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU

Author

Chaparro, M, primary, Garre, A, additional, Ricart, E, additional, García-Sánchez, V, additional, Taxonera, C, additional, Mañosa, M, additional, Vera Mendoza, I, additional, Mínguez, M, additional, Argüelles, F, additional, De Castro Parga, L, additional, Arroyo, M, additional, López-San Román, A, additional, Rivero Tirado, M, additional, Guardiola, J, additional, Martín Arranz, M D, additional, Beltrán, B, additional, Barrio, J, additional, Riestra, S, additional, García-Planella, E, additional, Calvet, X, additional, Alcaín, G, additional, Sicilia, B, additional, García, S, additional, Esteve, M, additional, Márquez, L, additional, Fernández Salazar, L, additional, Gutiérrez Casbas, A, additional, Piqueras, M, additional, Guerra, I, additional, Pérez Calle, J L, additional, Hinojosa, J, additional, Rodríguez, A, additional, Aldeguer, X, additional, García-Sepulcre, M, additional, Bujanda, L, additional, Martínez Montiel, P, additional, Llorente Poyatos, R, additional, Rodríguez Gutiérrez, C, additional, Merino, O, additional, Cabriada, J L, additional, Roncero, O, additional, Romero Cara, P, additional, Navarro-Llavat, M, additional, Ber, Y, additional, Madrigal, R, additional, Van Domselaar, M, additional, Barreiro-de Acosta, M, additional, Llao, J, additional, Ramos, L, additional, Riera, J, additional, Lucendo Villarín, A J, additional, Rodríguez González, E, additional, Huguet Malavés, J M, additional, Muñoz Villafranca, C, additional, Almela, P, additional, Charro, M, additional, Ramírez de la Piscina, P, additional, Sese, E, additional, Abad Lacruz, Á, additional, Khorrami, S, additional, Morales Alvarado, V J, additional, Legido Gil, J, additional, Trapero Martínez, A M, additional, Pajares, R, additional, Acevedo, J, additional, García Herola, A, additional, Hernández Villalba, L, additional, Muñoz, E, additional, Novella Durán, M T, additional, Menacho, M, additional, Navas López, V M, additional, Retamero, M D, additional, Domènech, E, additional, and Gisbert, J P, additional

Published
2018
Full Text
View/download PDF

81. P666 Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry

Author

Chaparro, M, primary, Garre, A, additional, Alfaro, I, additional, Iborra, M, additional, Mesonero, P, additional, Vera Mendoza, I, additional, Rodríguez, A, additional, Miquel-Cusachs, J, additional, Riestra, S, additional, Navarro, P, additional, De Castro Parga, L, additional, González-Muñoza, C, additional, Rivero Tirado, M, additional, Mañosa, M, additional, Fernández Salazar, L, additional, García-Sepulcre, M, additional, Guardiola, J, additional, Cabriada, J, additional, Gutiérrez Casbas, A, additional, Sicilia, B, additional, Pérez Calle, J L, additional, Piqueras, M, additional, Guerra, I, additional, Roncero, O, additional, Navarro-Llavat, M, additional, Sainz, E, additional, Barrio, J, additional, Calvet, X, additional, García, A, additional, Llorente Barrio, M, additional, Lorente, R, additional, Almela, P, additional, Madrigal, R, additional, Lucendo Villarín, A J, additional, Pajares, R, additional, Van Domselaar, M, additional, Legido Gil, J, additional, and Gisbert, J P, additional

Published
2018
Full Text
View/download PDF

82. P275 Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Spanish nationwide study based on the ENEIDA registry

Author

Guerra, I, primary, Bujanda, L, additional, Castro, J, additional, Merino, O, additional, Tosca, J, additional, Camps, B, additional, Gutiérrez, A, additional, Gordillo, J, additional, de Castro, L, additional, Iborra, M, additional, Carbajo, A Y, additional, Taxonera, C, additional, Rodriguez - Lago, I, additional, Mesonero, F, additional, de Francisco, R, additional, Gómez-Gómez, G J, additional, Chaparro, M, additional, Tardillo, C A, additional, Rivero, M, additional, Algaba, A, additional, Martín-Arranz, E, additional, Cañete, F, additional, Vicente, R, additional, Sicilia, B, additional, Antolín, B, additional, Prieto, V, additional, Márquez, L, additional, Benítez, J M, additional, Camo, P, additional, Piqueras, M, additional, Gargallo, C J, additional, Hinojosa, E, additional, Huguet, J M, additional, Pérez Calle, J L, additional, Van Domselaar, M, additional, Rodriguez, C, additional, Calvet, X, additional, Muñoz, M C, additional, García-Sepulcre, M F, additional, Bermejo, F, additional, Bañales, J M, additional, and Gisbert, J P, additional

Published
2018
Full Text
View/download PDF

83. P391 The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn’s disease but not in ulcerative colitis. A nationwide study from the Eneida registry

Author

Guasch, M, primary, Clos, A, additional, Ordás, I, additional, García-Sánchez, V, additional, Gisbert, J P, additional, Taxonera, C, additional, Vera, I, additional, Mínguez, M, additional, Guardiola, J, additional, López-Sanromán, A, additional, Rivero-Tirado, M, additional, Nos, P, additional, Gomollón, F, additional, Carbajo, A Y, additional, de Francisco, R, additional, Martín-Arranz, M D, additional, Garcia-Planella, E, additional, García-López, S, additional, de Castro, L, additional, Calvet, X, additional, Camargo, R, additional, Esteve, M, additional, Sicilia, B, additional, Andreu, M, additional, Macho, A, additional, Piqueras, M, additional, Bermejo, F, additional, Gutiérrez, A, additional, Busquets, D, additional, Martínez-Montiel, P, additional, Hinojosa, J, additional, Pérez-Calle, J L, additional, Bujanda, L, additional, Rodríguez-Pérez, A, additional, Lorente, R, additional, Jiménez, N, additional, Navarro-Llavat, M, additional, Cabriada, J L, additional, Camo, P, additional, Van Domselaar, M, additional, Rodríguez-González, E, additional, Rodríguez-Gutiérrez, C, additional, Huguet, J M, additional, Lucendo, A J, additional, Argüelles, F, additional, Almela, P, additional, Merino, O, additional, Calafat, M, additional, Ogueta, M, additional, Charro, M, additional, Llaó, J, additional, Muñoz, C, additional, Ramos, L, additional, Abad, Á, additional, Roncero, Ó, additional, Barreiro-de-Acosta, M, additional, Sesé, E, additional, Mañosa, M, additional, and Domènech, E, additional

Published
2018
Full Text
View/download PDF

84. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study

Author

Guerra I, Perez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, Chaparro M, Manosa M, Hinojosa E, Minguez M, Ortiz de Zarate J, Marquez L, Prieto V, Garcia-Sanchez V, Guardiola J, Esther Rodriguez G, Dolores Martin-Arranz M, Garcia-Tercero I, Sicilia B, Masedo A, Lorente R, Rivero M, Fernandez-Salazar L, GUTIERREZ A, Van Domselaar M, Lopez-SanRoman A, Ber Y, Garcia-Sepulcre M, Ramos L, Bermejo F, Gisbert J, and Spanish GETECCU Grp

Subjects
Male, Anti-Inflammatory Agents, Inflammatory bowel disease, Gastroenterology, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Crohn Disease, adalimumab, Immunology and Allergy, Incidence (epidemiology), Incidence, psoriasis, Prognosis, side effects, Crohn's disease, Cohort, 030211 gastroenterology & hepatology, Tumor necrosis factor alpha, Female, Cohort study, Adult, medicine.medical_specialty, Adolescent, 03 medical and health sciences, Gastrointestinal Agents, inflammatory bowel disease, Psoriasis, Internal medicine, medicine, Humans, Colitis, ulcerative colitis, business.industry, Tumor Necrosis Factor-alpha, Case-control study, Adalimumab, anti-TNF, medicine.disease, Infliximab, Withholding Treatment, Spain, Case-Control Studies, Physical therapy, Colitis, Ulcerative, business, infliximab, Follow-Up Studies
Abstract

Background: Psoriasis induced by anti-tumor necrosis factor-alpha (TNF) therapy has been described as a paradoxical side effect. Aim: To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. Methods: Patients with inflammatory bowel disease were identified from the Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes geneticos y Ambientales registry of Grupo Espanol de Trabajo en Enfermedad de Croh y Colitis Ulcerosa. Patients who developed psoriasis by anti-TNF drugs were the cases, whereas patients treated with anti-TNFs without psoriasis were controls. Cox regression analysis was performed to identify predictive factors. Results: Anti-TNF-induced psoriasis was reported in 125 of 7415 patients treated with anti-TNFs (1.7%; 95% CI, 1.4-2). The incidence rate of psoriasis is 0.5% (95% CI, 0.4-0.6) per patient-year. In the multivariate analysis, the female sex (HR 1.9; 95% CI, 1.3-2.9) and being a smoker/former smoker (HR 2.1; 95% CI, 1.4-3.3) were associated with an increased risk of psoriasis. The age at start of anti-TNF therapy, type of inflammatory bowel disease, Montreal Classification, and first anti-TNF drug used were not associated with the risk of psoriasis. Topical steroids were the most frequent treatment (70%), achieving clinical response in 78% of patients. Patients switching to another anti-TNF agent resulted in 60% presenting recurrence of psoriasis. In 45 patients (37%), the anti-TNF therapy had to be definitely withdrawn. Conclusions: The incidence rate of psoriasis induced by anti-TNF therapy is higher in women and in smokers/former smokers. In most patients, skin lesions were controlled with topical steroids. More than half of patients switching to another anti-TNF agent had recurrence of psoriasis. In most patients, the anti-TNF therapy could be maintained.

Published
2016

85. INFLAMMATORY BOWEL DISEASE Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study

Author

Marin-Jimenez, I, Nos, P, Domenech, E, Riestra, S, Gisbert, JP, Calvet, X, Cortes, X, Iglesias, E, Huguet, JM, Taxonera, C, Fernandez, R, Carpio, D, Gutierrez, A, Guardiola, J, Laria, LC, Sicilia, B, Bujanda, L, Cea-Calvo, L, Romero, C, Rincon, O, Julia, B, and Panes, J

Abstract

OBJECTIVES: New e-health technologies can improve patient-physician communication and contribute to optimal patient care. We compared the diagnostic performance of the Simple Clinical Colitis Activity Index (SCCAI) self-administered by patients with ulcerative colitis (UC) at home (through a website) with the in-clinic gastroenterologist-assessed SCCAI. METHODS: Patients were followed-up over 6 months. At months 3 and 6, patients completed the SCCAI online at home; within 48 h, gastroenterologists (blinded to patients' scores) completed the in-clinic SCCAI (reference). SCCAI scores were dichotomized to remission or active disease, and SCCAI changes in disease activity from month 3 to 6 were classed as worsening, stability, or improvement. RESULTS: A total of 199 patients (median age: 38 years; 56% female) contributed with 340 pairs of questionnaires. Correlation of SCCAI scores by patients and physicians was good (Spearman's rho=0.79), with 85% agreement for remission or activity (95% CI: 80.8-88.6, kappa=0.66). The negative predictive value for active disease was 94.5% (91.4-96.6); the positive predictive value was 68.0% (58.8-69.2). Agreement between patient and physician was higher in the 168 month 6 pairs than in the 172 month 3 pairs of questionnaires (89.3% (83.6-93.1) vs. 80.8% (74.2-86.0), P=0.027). CONCLUSIONS: In patients with UC, SCCAI self-administration via an online tool resulted in a high percentage of agreement with evaluation by gastroenterologists, with a remarkably high negative predictive value for disease activity. Remote monitoring of UC patients is possible and might reduce hospital visits.

Published
2016

86. Effectiveness and safety of vedolizumab for the induction of remission in inflammatory bowel disease

Author

Chaparro M, Sierra-Ausin M, Mesonero F, Maroto N, de Castro C, Garcia-Sanchez V, Lucendo A, Busquets D, Barreiro-de Acosta M, Marin-Jimenez I, Beltran B, Belmonte L, Bermejo F, Minguez M, Pajares R, Pineda J, Sicilia B, Martin-Rodriguez D, Gutierrez A, Rubio S, Tercero I, Piqueras M, Ginard D, Jucha B, Villafranca C, Martin-Arranz M, Romero L, Bonilla E, Echarri A, Forcelledo J, Donday M, Ramas M, and Gisbert J

Published
2016

87. Estudio comparativo prospectivo multicéntrico aleatorizado del tratamiento endoscópico de las estenosis en la Enfermedad de Crohn: prótesis metálica autoexpandible vs. dilatación con balón (estudio PROTDILAT)

Author

Andújar Murcia, X, additional, Loras, C, additional, Gornals, JB, additional, Sanchiz, V, additional, Brullet, E, additional, Sicilia, B, additional, Naranjo, A, additional, Dueñas, C, additional, González-Huix, F, additional, and Esteve Comas, M, additional

Published
2017
Full Text
View/download PDF

97. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre cribado de displasia en pacientes con enfermedad inflamatoria intestinal

Author

Sicilia, B., Vicente, R., Arias, L., Echarri, A., Zabana, Y., Mañosa, M., Beltrán, B., and Barreiro-de Acosta, M.

Abstract

Los pacientes con enfermedades inflamatorias intestinales de localización colónica tienen mayor riesgo de desarrollar cáncer colorrectal que la población general, por lo que precisan de técnicas endoscópicas de cribado con intervalos de seguimiento basados en los diferentes factores de riesgo descritos.

Published
2021
Full Text
View/download PDF

98. The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry

Author

Guasch, M., Clos, A., Ordas, I., Garcia-Sanchez, V., Gisbert, J. P., Taxonera, C., Vera, I., Minguez, M., Guardiola, J., Lopez-Sanroman, A., Rivero-Tirado, M., Nos, P., Gomollon, F., Carbajo, A. Y., Francisco, R., Martin-Arranz, M. D., Garcia-Planella, E., Garcia-Lopez, S., Castro, L., Calvet, X., Camargo, R., Esteve, M., Sicilia, B., Andreu, M., Macho, A., Piqueras, M., Bermejo, F., Gutierrez, A., Busquets, D., Martinez-Montiel, P., Hinojosa, J., Perez-Calle, J. L., Luis Bujanda, Rodriguez-Perez, A., Lorente, R., Jimenez, N., Navarro-Llavat, M., Cabriada, J. L., Camo, P., Domselaar, M., Rodriguez-Gonzalez, E., Rodriguez-Gutierrez, C., Huguet, J. M., Lucendo, A. J., Arguelles, F., Almela, P., Merino, O., Calafat, M., Ogueta, M., Charro, M., Llao, J., Munoz, C., Ramos, L., Abad, A., Roncero, O., Barreiro-De-Acosta, M., Sese, E., Manosa, M., and Domenech, E.

99. Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Spanish nationwide study based on the ENEIDA registry

Author

Guerra, I., Luis Bujanda, Castro, J., Merino, O., Tosca, J., Camps, B., Gutierrez, A., Gordillo, J., Castro, L., Iborra, M., Carbajo, A. Y., Taxonera, C., Rodriguez-Lago, I., Mesonero, F., Francisco, R., Gomez-Gomez, G. J., Chaparro, M., Tardillo, C. A., Rivero, M., Algaba, A., Martin-Arranz, E., Canete, F., Vicente, R., Sicilia, B., Antolin, B., Prieto, V., Marquez, L., Benitez, J. M., Camo, P., Piqueras, M., Gargallo, C. J., Hinojosa, E., Huguet, J. M., Perez Calle, J. L., Domselaar, M., Rodriguez, C., Calvet, X., Munoz, M. C., Garcia-Sepulcre, M. F., Bermejo, F., Banales, J. M., and Gisbert, J. P.

100. Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU

Author

Chaparro, M., Garre, A., Ricart, E., Garcia-Sanchez, V., Taxonera, C., Manosa, M., Vera Mendoza, I., Minguez, M., Arguelles, F., Castro Parga, L., Arroyo, M., Lopez-San Roman, A., Rivero Tirado, M., Guardiola, J., Martin Arranz, M. D., Beltran, B., Barrio, J., Riestra, S., Garcia-Planella, E., Calvet, X., Alcain, G., Sicilia, B., Garcia, S., Esteve, M., Marquez, L., Fernandez Salazar, L., Gutierrez Casbas, A., Piqueras, M., Guerra, I., Perez Calle, J. L., Hinojosa, J., Rodriguez, A., Aldeguer, X., Garcia-Sepulcre, M., Bujanda, L., Martinez Montiel, P., Llorente Poyatos, R., Rodriguez Gutierrez, C., Merino, O., Cabriada, J. L., Octavio Roncero, Romero Cara, P., Navarro-Llavat, M., Ber, Y., Madrigal, R., Domselaar, M., Barreiro-De Acosta, M., Llao, J., Ramos, L., Riera, J., Lucendo Villarin, A. J., Rodriguez Gonzalez, E., Huguet Malaves, J. M., Munoz Villafranca, C., Almela, P., Charro, M., Ramirez La Piscina, P., Sese, E., Abad Lacruz, A., Khorrami, S., Morales Alvarado, V. J., Legido Gil, J., Trapero Martinez, A. M., Pajares, R., Acevedo, J., Garcia Herola, A., Hernandez Villalba, L., Munoz, E., Novella Duran, M. T., Menacho, M., Navas Lopez, V. M., Retamero, M. D., Domenech, E., and Gisbert, J. P.

Catalog

Books, media, physical & digital resources
See catalog results